Pain relief — is there an alternative to NSAIDs?
A.V. Garkavi1, G.M. Kavalerskiy1, S.V.Terekhin1, V.A. Meshcheryakov2
1 Sechenov University, Moscow
2 Ruza District Hospital
Aim: to develop a scheme of conservative therapy of exacerbation of osteoarthrosis to minimize the NSAIDs side effects.
Patients and Methods: 358 patients (age 31–82) with osteoarthrosis of the knee joint of I–III degree in the acute stage with
a pain syndrome of 48–83 points on a visual analogue scale (VAS) were included in the study. Patients were divided into
3 groups: group 1 (n = 96) received diclofenac 150 mg / day; group 2 (n = 52) received Traumeel S for 1 tablet 3 times
a day; group 3 (n = 209) received a complex therapy: diclofenac 100 mg / day + Traumeel S (1 t х 3 times a day). The duration
of observation was 1 month. With a decrease in pain up to 15 points on the VAS scale NSAIDs were cancelled.
Results and Discussion: in group 1 on the 1st day the average value of the pain syndrome decreased by 16.2 points by VAS, on the 3d day it reached 24.5 points. By the 3d day NSAIDs were canceled for 23 patients, by the 4th day — for 22 patients more, by the 7th day — for all the patients. In group 2, the pain syndrome decreased more slowly (by 9.9 points during the first
3 days), by the 4th and 5th days it decreased by 22 and 30.2 points, respectively. By the end of the observation, the average score was 8.6 points. In the third group: for the 1st day the pain decreased by 17.3 points. By the 3d day the value was comparable to the effect in group 1, NSAIDs were cancelled for 20 patients. By the 4th and 5th days the average pain value in group 3 was lower than in group 1. By the 6th day NSAIDs were cancelled for all the patients. The average total dose of NSAIDs was 492 mg in group 1, and 307 mg in group 3.
Conclusions: a combined treatment with NSAIDs and Traumeel S allows to achieve a rapid and stable therapeutic effect with reduction of the total dose of NSAIDs by a factor of 1.6 in comparison with monotherapy.
Key words: osteoarthrosis, pain syndrome, visual analogue scale (VAS), non-steroidal anti-inflammatory drugs (NSAIDs), Traumeel S.
For citation: Garkavi A.V., Kavalerskiy G.M., Terekhin S.V., Meshcheryakov V.A. The informative value of diagnostic tests
in urogenital tuberculosis screening // RMJ. Medical Review. 2018. № 1(I). P. 50–53.
References
1. Миронов С. П., Омельяненко Н. П., Орлецкий А. К. и др. Остеоартроз: современное состояние проблемы (аналитический обзор) // Вестник травматологии и ортопедии им. Н. Н. Приорова. 2001. № 2. С. 96–99 [Mironov S.P., Omel’janenko N.P., Orleckij A. K. i dr. Osteoartroz: sovremennoe sostojanie problemy (analiticheskij obzor) // Vestnik travmatologii i ortopedii im. N. N. Priorova. 2001. № 2. С. 96–99 (in Russian)].
2. Пихлак А. Э., Гаркави А. В., Логачев В. А., Терешенков В. П. Остеоартроз: клиника, диагностика, лечение. Учебное пособие для врачей. М.: ИД «Медпрактика-М», 2013. 144 с. [Pikhlak A.E., Garkavi A. V., Logachev V. A., Tereshenkov V. P. Osteoartroz: klinika, diagnostika, lecheniye. Uchebnoye posobiye dlya vrachey. M.: ID «Medpraktika-M», 2013. 144 s. (in Russian)].
3. Harrysson O. L., Robertsson O., Nayfeh F. Higher cumulative revision rate of knee arthroplasties in younger patients with osteoarthritis // Clin.Orthop. 2008. Vol. 421. P. 162–168.
4. National Joint Registry (United Kingdom) — 8th Annual report. 2011. 70 p.
5. Алексеева Л. И., Зайцева Е. М. Клинические подходы к лечению остеоартроза // Русский медицинский журнал. 2006. Т. 14. № 6 (258). С. 450–453 [Alekseeva L.I., Zajceva E. M. Klinicheskie podhody k lecheniju osteoartroza // Russkij medicinskij zhurnal. 2006. T. 14. № 6 (258). S. 450–453 (in Russian)].
6. Багирова Г. Г., Майко О. Ю. Остеоартроз: эпидемиология, клиника, диагностика, лечение. М.: Арнебия, 2005. 224 с. [Bagirova G.G., Majko O. Ju. Osteoartroz: jepidemiologija, klinika, diagnostika, lechenie. M.: Arnebija, 2005. 224 s. (in Russian)].
7. Носков С. М. Консервативное лечение остеоартроза. М.: ГЭОТАР-Медиа, 2012. 208 с. [Noskov S. M. Konservativnoe lechenie osteoartroza. М.: GJeOTAR-Media, 2012. 208 s. (in Russian)].
8. Каратеев А. Е. Гастродуоденальная безопасность селективных ингибиторов циклооксигеназы-2: проверка практикой // Терапевтический архив. 2005. № 5. С. 69–72 [Karateev A. E. Gastroduodenal’naja bezopasnost’ selektivnyh ingibitorov ciklooksigenazy-2: proverka praktikoj // Terapevticheskij arhiv. 2005. № 5. S. 69–72 (in Russian)].
9. Коршунов Н. И., Ершова О. Б. Современные подходы к фармакотерапии остеоартроза // Consilium medicum. 2006. № 2. С. 34–38 [Korshunov N.I., Ershova O. B. Sovremennye podhody k farmakoterapii osteoartroza // Consilium medicum. 2006. № 2. S. 34–38 (in Russian)].
10. Лила А. М. Современная фармакотерапия остеоартроза // Terra medica. 2005. № 1 (37). C. 3–9 [Lila A. M. Sovremennaja farmakoterapija osteoartroza // Terra medica. 2005. № 1 (37). S. 3–9 (in Russian)].
11. Ding C. Do NSAID affect the progression of osteoarthritis? // Inflammation. 2002. Vol. 26 (3). P. 139–142.
12. Lozada C., del Rio E., Reitberg D.P. et al. Risk benefit of co-administered Traumeel® (Tr14) and Zeel® (Ze14) intra-articular (IA) injections in patients with moderate-to-severe pain associated with OA of the knee (OAK) (THU0441) //Ann. Rheum. Dis. 2015. Vol. 74. Suppl. 2. P. 4268.
13. St. Laurent III G., Seilheimer B., Tackett M. et al. Deep sequencing transcriptome analysis of the effect of Traumeel versus diclofenac therapeutic action in wound healing // Ann Rheum Dis. 2017. Vol. 76. Suppl. 2. P. 202.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
